Shares of Kala Pharmaceuticals, Inc. (KALA) are rising more than 6% Friday morning at $16.43.
The company today said Combangio, Inc., a unit of Kala, has been awarded a $15 million grant by the California Institute for Regenerative Medicine (CIRM) to support the company’s ongoing study of KPI-012 for the treatment of persistent corneal epithelial defect (PCED).
KALA has traded in the range of $3.54-$56.72 in the last 1 year.
Source: Read Full Article
Lates News:
-
Cryptos Plunge Amidst Bad News, Bitcoin Drops To $25.4k
-
$ETH Had a Great July, Vastly Outperforming Bitcoin
-
Cryptos Rise Amidst The Dollar's Retreat
-
CureVac Rallies On Positive Data From Its COVID-19, Flu Vaccine Candidates
-
Cardio Diagnostics Jumps After Launching Blood Test For Early Detection Of Coronary Heart Disease